Current batch context: NAD-2026-500
doi: 10.1007/s13300-011-0002-3
Kayla Zafar, BA, can be reached at [email protected].
For example, if phenytoin levels are therapeutic, the administration of a drug competing for protein binding could double the free phenytoin level (if protein binding decreases from 90% to 80%)
IGF-1 LR3 is investigated in preclinical research for IGF-1R signaling, PI3K/Akt/mTOR pathway activation, skeletal muscle protein synthesis, and metabolic pathway research
-MSH Analog Cyclic Heptapeptide University of Arizona Originator Literature Reported Mechanism (Literature) Non-Selective Melanocortin Receptor Agonist Pan-MCR activation (MC1R, MC3R, MC4R, MC5R) Al-Obeidi and colleagues (1989, PMID 2555512) designed Melanotan II as a non-selective melanocortin receptor agonist with 100-fold enhanced melanotropic potency versus -MSH in the lizard skin bioassay